SYS-CON MEDIA Authors: Nicole Gorman, RealWire News Distribution, Gathering Clouds, CloudCommons 2012

News Feed Item

Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2013 On October 29, 2012
By PR Newswire
Article Rating:
October 23, 2012 05:47 PM EDT
Reads:
 213

BOULDER, Colo., Oct. 23, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2013 on Monday, October 29, 2012, and will hold a conference call on Tuesday, October 30, 2012 at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information

Date:

Tuesday, October 30, 2012

Time:

9:00 a.m. eastern time

Toll-Free:

866-383-8119

Toll:

617-597-5344

Pass Code:

70615778

Webcast & Conference Call Slides:

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

 

A replay of the call will be available as a webcast on www.arraybiopharma.com

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.  For more information on Array, please go to www.arraybiopharma.com.

SOURCE Array BioPharma Inc.

Published October 23, 2012 – Reads 213
Copyright © 2012 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.